Moderna Expands Covid-19 Vaccine Trial to 12-18 Age Group

Author:
Publish date:
Video Duration:
2:48

Moderna (MRNA) - Get Report has expanded its current phase 2/3 trial study of its Covid-19 vaccine candidate to include adolescents between the ages of 12 and 18.

Moderna on Thursday said it intends to dose some 3,000 adolescent participants in the U.S. ages 12 to less than 18 years with either  a placebo or a 100 μg dose.

“Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year,” Moderna said in a statement.

Researchers studying the virus have noted that morbidity and mortality associated with Covid-19 infections have been significantly lower in young children and adolescents, though reports of Covid-19 symptoms and deaths have been recorded.

As of October, the American Academy of Pediatrics reported that nearly 700 000 child and adolescent Covid-19 cases had been reported in the U.S., roughly 10.7% of all cases, with more than 5,000 cumulative hospitalizations and more than 100 deaths.

The trial expansion comes as Pfizer's (PFE) - Get Report Covid-19 vaccine receives a final review from a Food and Drug Administration advisory committee that could authorize the first coronavirus vaccine in the U.S.

Latest Videos From TheStreet and Jim Cramer:

Related Videos